Table 1.

Clinical trials and discovery projects targeting CD19

Biologic compoundTypeMechanism of actionPhase (initiation date)
MT-103 (blinatumomab) Micromet, Inc.Bispecific scFv anti-CD19/anti-CD3 BiTET-cell recruitment and activationI/II/III (2007) Pivotal trial for MDR+ ALL
SAR3419 Sanofi-Aventis/ImmunoGen, Inc.Humanized anti-CD19 mAb conjugated to maytansinoid DM4ADC (tubulin binder)I/II (2007)
MEDI-551 MedImmune/Astra-ZenecaGlycoengineered humanized anti-CD19 mAb (BioWa's Potelligent)Naked antibody high-affinity FcγRIII-enhanced ADCCI (2010)
MOR-208/XmAb5574 Xencor/MorphosysFc engineered humanized anti-CD19 mAbNaked antibody high-affinity FcγRIII-enhanced ADCCI (2010)
MDX-1342 Medarex/Bristol-Myers SquibbGlycoengineered fully human anti-CD19 mAb (BioWa's Potelligent)Naked antibody high-affinity FcγRIII-enhanced ADCCI (2008, on hold)
Combotox University of Texas Southwestern/AbiogenMixture of chimeric anti-CD19 mAb HD37 and anti-CD22 mAb RFB4, both conjugated to deglycosylated ricin A-chain (HD37-dgA + RFB4-dgA)Immunotoxin conjugate with deglycosylated ricin A-chainI (2005)
DI-B4Merck KGaA/Cancer Research UKChimeric anti-CD19 mAb monoclonal antibodyNaked antibody ADCCI (2010)
SGN-19A Seattle GeneticsFully human anti-CD19 mAb (hBU12) conjugated to auristatin (vc-MMAE)ADC (tubulin binder)Discovery
MDX-1206 Medarex/Bristol-Myers SquibbFully human anti-CD19 mAb (MDX1435) conjugated to duocarmycin (vc-MGBAA)ADC (DNA alkylating agent)Discovery
AFM-11 Affimed Therapeutics AGTetravalent tandem antibody (TandAb) anti-CD19/anti-CD3T-cell recruitmentDiscovery
AFM-12 Affimed Therapeutics AGTetravalent tandem antibody (TandAb) anti-CD19/anti-CD16NK cell recruitmentDiscovery